Report Code: CMI43193

Published Date: March 2024

Pages: 320+

Category: Healthcare

Report Snapshot

CAGR: 8.2%
105.2B
2023
113.8B
2024
231.4B
2033

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Amgen Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • AbbVie Inc.
  • Genentech Inc. (a subsidiary of Roche)
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Cancer Monoclonal Antibodies Market is expected to record a CAGR of 8.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 113.8 Billion. By 2033, the valuation is anticipated to reach USD 231.4 Billion.

The Cancer Monoclonal Antibodies Market involves the development, production, and commercialization of therapeutic antibodies designed to target specific cancer cells or proteins. These monoclonal antibodies play a pivotal role in cancer treatment and diagnosis by facilitating targeted therapies and enabling precise identification of cancer biomarkers.

The market is driven by advancements in biotechnology, increased focus on personalized medicine, and a growing global incidence of cancer. Key players engage in research and development, strategic collaborations, and technological innovations to meet the rising demand for effective and targeted cancer monoclonal antibody solutions in the continually evolving healthcare landscape.

Cancer Monoclonal Antibodies Market – Significant Growth Factors

The Cancer Monoclonal Antibodies Market presents significant growth opportunities due to several factors:

  • Increasing Cancer Incidence: The growing prevalence of cancer is a primary driver, necessitating advanced and targeted therapies like monoclonal antibodies to address the rising disease burden.
  • Advancements in Biotechnology: Ongoing developments in biotechnology contribute to the design of more effective monoclonal antibodies, enhancing their specificity, efficacy, and potential applications in cancer treatment.
  • Emphasis on Personalized Medicine: The shift towards personalized medicine fuels the demand for monoclonal antibodies as they offer tailored treatments based on individual patient characteristics, improving therapeutic outcomes.
  • R&D Investments: Significant investments in research and development by pharmaceutical companies drive innovation in monoclonal antibodies, leading to the discovery of novel treatments and expanded applications across various cancer types.
  • Diagnostic Expansion: There is an opportunity to expand the application of monoclonal antibodies in diagnostics, including early cancer detection and monitoring, offering a comprehensive approach to cancer care.
  • Global Market Expansion: With increasing awareness and adoption, especially in emerging markets, there is an opportunity for global market expansion. Collaborations and strategic partnerships can facilitate access to monoclonal antibody therapies, addressing unmet medical needs on a broader scale.

Cancer Monoclonal Antibodies Market – Mergers and Acquisitions

The Cancer Monoclonal Antibodies Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Cancer Monoclonal Antibodies Market include:

  • In 2023, Merck initiated strategic collaborations with BenevolentAI and Exscientia, both based in the U.K., aiming to bolster AI-driven drug discovery. These partnerships target the creation of novel clinical development drug candidates, focusing on first-in-class and best-in-class potential across pivotal therapeutic areas, including oncology, neurology, and immunology.
  • In 2023, AstraZeneca India partnered with Roche Diagnostics India to enhance diagnostic testing for breast cancer patients, particularly focusing on streamlining HER2 diagnostics. This collaboration aims to leverage new advancements in the field, improving precision and efficiency in breast cancer diagnostics.
  • In 2022, Helio Genomics, in partnership with Fulgent Genetics, secured a new Category I CPT code from the AMA for HelioLiver, enhancing the adoption of advanced surveillance tests for liver cancer in the U.S. This achievement expands the company’s product portfolio and market reach.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Cancer Monoclonal Antibodies Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Cancer Monoclonal Antibodies Market India Pharmaceutical Market Breast Cancer Mammography Screening Market
CAGR 8.2% (Approx) CAGR 9.48% (Approx) CAGR 8.6% (Approx)
USD 231.4 Billion by 2033 USD 129.49 Billion by 2032 USD 8.7 Billion by 2032

Cancer Monoclonal Antibodies Market – Significant Threats

The Cancer Monoclonal Antibodies Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Regulatory Challenges: Stringent regulatory approval processes pose a significant threat, as delays or rejections in obtaining approvals can hinder the market entry and commercialization of monoclonal antibodies for cancer treatment.
  • High Development Costs: The substantial costs associated with research, development, and clinical trials present financial challenges. High development costs may limit the number of players entering the market and impact pricing strategies.
  • Competition and Market Saturation: Intense competition among pharmaceutical companies and the potential for market saturation pose threats. The crowded landscape may lead to pricing pressures and increased challenges in differentiating monoclonal antibody products.
  • Emergence of Alternative Therapies: Advances in alternative cancer therapies, such as gene therapies or small molecule drugs, represent a threat. These alternatives may offer new treatment modalities, diverting attention and investment away from monoclonal antibody-based treatments.
  • Global Economic Uncertainty: Economic downturns and uncertainties on a global scale can impact healthcare budgets, potentially leading to reduced funding for research and development, and limiting investment in monoclonal antibody development and adoption.

Global Cancer Monoclonal Antibodies Market 2024–2033 (By Route of Administration)

www.custommarketinsight.com

Category-Wise Insights:

By Route of Administration

  • Intravenous (IV): Intravenous administration involves delivering Cancer Monoclonal Antibodies directly into the bloodstream. This route allows rapid and systemic distribution, enhancing therapeutic efficacy. A trend in this segment includes the development of novel IV formulations, optimizing infusion durations, and improving patient comfort, fostering increased adoption.
  • Subcutaneous (SC): Subcutaneous administration involves injecting Cancer Monoclonal Antibodies under the skin. This route provides a convenient and less invasive option, reducing the treatment burden for patients. A trend in this segment includes the development of subcutaneous formulations, promoting self-administration and improving patient adherence.
  • Others: Other administration routes may include innovative methods such as intramuscular or intrathecal. Emerging trends in this segment involve exploring alternative administration routes to enhance therapeutic outcomes, minimize side effects, and address specific patient needs in the Cancer Monoclonal Antibodies Market.

By Application

  • Non-Hodgkin Lymphoma: Non-Hodgkin Lymphoma application in the Cancer Monoclonal Antibodies Market involves targeted therapies addressing lymphatic system cancers. Trends include the development of novel antibodies specifically designed for diverse Non-Hodgkin Lymphoma subtypes, improving treatment precision and efficacy.
  • Hodgkin Lymphoma: Hodgkin Lymphoma segment focuses on monoclonal antibodies tailored for Hodgkin’s lymphoma. Current trends center around personalized therapies, utilizing innovative antibodies to enhance treatment outcomes, minimize side effects, and improve patient quality of life.
  • Acute Myelogenous Leukemia: Acute Myelogenous Leukemia applications involve monoclonal antibodies targeting myeloid cells. Ongoing trends emphasize combination therapies, utilizing antibodies to enhance the effectiveness of existing treatments and reduce the risk of relapse in AML patients.
  • Chronic Lymphocytic Leukemia: Chronic Lymphocytic Leukemia segment focuses on antibodies addressing this common leukemia type. Trends include the development of next-generation monoclonal antibodies, with an emphasis on improving overall response rates and prolonging progression-free survival for CLL patients.
  • Solid Tumor: Solid Tumor applications encompass monoclonal antibodies designed for various cancer types with solid masses. Trends involve expanding indications to cover a broader spectrum of solid tumors, enhancing the versatility of monoclonal antibody therapies in cancer treatment.
  • Epithelial Tumor: Epithelial Tumor segment involves monoclonal antibodies targeting cancers originating from epithelial tissues. Current trends focus on precision medicine, utilizing biomarker-specific antibodies for early detection and tailored treatment of epithelial tumors.
  • Others: The “Others” category includes diverse applications beyond the specified categories. Trends within this segment revolve around identifying unique cancer types and developing monoclonal antibodies tailored to specific molecular targets, fostering advancements in precision medicine and expanding therapeutic options.

Global Cancer Monoclonal Antibodies Market 2024–2033 (By End-Users)

www.custommarketinsight.com

By End Users

  • Hospitals: Hospitals are primary users of Cancer Monoclonal Antibodies, employing them for cancer diagnosis and treatment. Trends include increased adoption of monoclonal antibody therapies within hospital settings, enhancing comprehensive cancer care and providing patients with advanced treatment options.
  • Homecare: Homecare involves administering Cancer Monoclonal Antibodies outside hospital settings. A rising trend involves developing home infusion programs, enabling patients to receive treatment at home, enhancing convenience, and minimizing hospital visits.
  • Specialty Centers: Specialty centers focus on specific cancer types or treatment modalities. In the Cancer Monoclonal Antibodies Market, the trend is towards establishing specialized centers, ensuring targeted and efficient monoclonal antibody therapies for specific patient populations.
  • Others: Other end-users encompass various healthcare facilities and clinics. The trend involves diversification in testing services, expanding accessibility, and exploring partnerships with technology providers to integrate Cancer Monoclonal Antibodies into a broader spectrum of healthcare services.

By Distribution Channel

  • Hospital Pharmacy: Hospital pharmacies are crucial distribution channels for Cancer Monoclonal Antibodies, ensuring accessibility to patients. Trends include an increasing focus on in-house production, streamlined supply chains, and collaborations with pharmaceutical companies to enhance the availability and timely delivery of monoclonal antibody therapies within healthcare institutions.
  • Online Pharmacy: Online pharmacies provide a convenient avenue for patients to access Cancer Monoclonal Antibodies. Trends involve the growing adoption of telehealth, digital prescriptions, and increased patient education on online platforms, enhancing accessibility and patient engagement in remote or home-based settings.
  • Retail Pharmacy: Retail pharmacies play a vital role in distributing Cancer Monoclonal Antibodies to the wider population. Trends include personalized patient consultations, point-of-care services, and the integration of cancer screening and diagnostic services within retail settings, enhancing the accessibility and convenience of monoclonal antibody therapies.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 113.8 Billion
Projected Market Size in 2033 USD 231.4 Billion
Market Size in 2023 USD 105.2 Billion
CAGR Growth Rate 8.2% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Route of Administration, Application, End-Users, Distribution Channel and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Cancer Monoclonal Antibodies Market – Regional Analysis

The Cancer Monoclonal Antibodies Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In North America, there is a notable trend towards increased adoption of Cancer Monoclonal Antibodies, driven by a growing emphasis on precision medicine. The region experiences a surge in collaborations between pharmaceutical companies and research institutions, fostering innovation and the development of novel monoclonal antibody therapies.
  • Europe: Europe showcases a trend of regulatory alignment and standardization in Cancer Monoclonal Antibodies usage. The region emphasizes cross-border collaborations, ensuring consistent treatment approaches and facilitating efficient data sharing for enhanced cancer research and therapeutic advancements.
  • Asia-Pacific: The Asia-Pacific region witnesses a trend of expanding healthcare infrastructure, leading to improved accessibility to Cancer Monoclonal Antibodies. Collaborations between local and global pharmaceutical companies drive innovation, with a focus on adapting monoclonal antibody therapies to address the specific cancer epidemiology of the region.
  • Latin America, Middle East, and Africa (LAMEA): In LAMEA, there is a noticeable trend towards addressing healthcare disparities through increased investment in Cancer Monoclonal Antibodies. Initiatives focus on enhancing affordability and availability, with collaborations between governments, pharmaceutical companies, and NGOs aiming to bridge gaps in cancer care and diagnostics.

Global Cancer Monoclonal Antibodies Market 2024–2033 (By Billion)

www.custommarketinsight.com

Competitive Landscape – Cancer Monoclonal Antibodies Market

The Cancer Monoclonal Antibodies Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

  • Amgen Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • AbbVie Inc.
  • Genentech Inc. (a subsidiary of Roche)
  • Biogen Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Seattle Genetics Inc.
  • Takeda Pharmaceutical Company Limited
  • Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Bristol Myers Squibb Company
  • Johnson & Johnson
  • Novartis International AG
  • Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players entering the cancer monoclonal antibodies market, such as emerging biotech firms and startups, often adopt innovative technologies and strategic partnerships for market entry. Key players dominating the market include established pharmaceutical giants like F. Hoffmann-La Roche, Merck, and Johnson & Johnson.

These industry leaders leverage extensive research and development investments, global distribution networks, and diverse product portfolios. Their dominance is fortified by continuous innovation, strategic acquisitions, and collaborations, ensuring a competitive edge and market leadership in the dynamic landscape of Cancer Monoclonal Antibodies.

The Cancer Monoclonal Antibodies Market is segmented as follows:

By Route of Administration

  • Intravenous (IV)
  • Subcutaneous (SC)
  • Others

By Application

  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Acute Myelogenous Leukemia
  • Chronic Lymphocytic Leukemia
  • Solid Tumor
  • Epithelial Tumor
  • Others

By End-Users

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Cancer Monoclonal Antibodies Market, (2024 – 2033) (USD Billion)
    • 2.2 Global Cancer Monoclonal Antibodies Market: snapshot
  • Chapter 3. Global Cancer Monoclonal Antibodies Market – Industry Analysis
    • 3.1 Cancer Monoclonal Antibodies Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing Cancer Incidence
      • 3.2.2 Advancements in Biotechnology
      • 3.2.3 Emphasis on Personalized Medicine
      • 3.2.4 R&D Investments
      • 3.2.5 Diagnostic Expansion
      • 3.2.6 Global Market Expansion.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Route of Administration
      • 3.7.2 Market Attractiveness Analysis By Application
      • 3.7.3 Market Attractiveness Analysis By End-Users
      • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • Chapter 4. Global Cancer Monoclonal Antibodies Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Cancer Monoclonal Antibodies Market: company market share, 2024
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Cancer Monoclonal Antibodies Market – Route of Administration Analysis
    • 5.1 Global Cancer Monoclonal Antibodies Market Overview: By Route of Administration
      • 5.1.1 Global Cancer Monoclonal Antibodies Market Share, By Route of Administration, 2024 and – 2033
    • 5.2 Intravenous (IV)
      • 5.2.1 Global Cancer Monoclonal Antibodies Market by Intravenous (IV), 2024 – 2033 (USD Billion)
    • 5.3 Subcutaneous (SC)
      • 5.3.1 Global Cancer Monoclonal Antibodies Market by Subcutaneous (SC), 2024 – 2033 (USD Billion)
    • 5.4 Others
      • 5.4.1 Global Cancer Monoclonal Antibodies Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 6. Global Cancer Monoclonal Antibodies Market – Application Analysis
    • 6.1 Global Cancer Monoclonal Antibodies Market Overview: By Application
      • 6.1.1 Global Cancer Monoclonal Antibodies Market Share, By Application, 2024 and – 2033
    • 6.2 Non-Hodgkin Lymphoma
      • 6.2.1 Global Cancer Monoclonal Antibodies Market by Non-Hodgkin Lymphoma, 2024 – 2033 (USD Billion)
    • 6.3 Hodgkin Lymphoma
      • 6.3.1 Global Cancer Monoclonal Antibodies Market by Hodgkin Lymphoma, 2024 – 2033 (USD Billion)
    • 6.4 Acute Myelogenous Leukemia
      • 6.4.1 Global Cancer Monoclonal Antibodies Market by Acute Myelogenous Leukemia, 2024 – 2033 (USD Billion)
    • 6.5 Chronic Lymphocytic Leukemia
      • 6.5.1 Global Cancer Monoclonal Antibodies Market by Chronic Lymphocytic Leukemia, 2024 – 2033 (USD Billion)
    • 6.6 Solid Tumor
      • 6.6.1 Global Cancer Monoclonal Antibodies Market by Solid Tumor, 2024 – 2033 (USD Billion)
    • 6.7 Epithelial Tumor
      • 6.7.1 Global Cancer Monoclonal Antibodies Market by Epithelial Tumor, 2024 – 2033 (USD Billion)
    • 6.8 Others
      • 6.8.1 Global Cancer Monoclonal Antibodies Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 7. Global Cancer Monoclonal Antibodies Market – End-Users Analysis
    • 7.1 Global Cancer Monoclonal Antibodies Market Overview: By End-Users
      • 7.1.1 Global Cancer Monoclonal Antibodies Market Share, By End-Users , 2024 and – 2033
    • 7.2 Hospitals
      • 7.2.1 Global Cancer Monoclonal Antibodies Market by Hospitals, 2024 – 2033 (USD Billion)
    • 7.3 Homecare
      • 7.3.1 Global Cancer Monoclonal Antibodies Market by Homecare, 2024 – 2033 (USD Billion)
    • 7.4 Speciality Centres
      • 7.4.1 Global Cancer Monoclonal Antibodies Market by Speciality Centres, 2024 – 2033 (USD Billion)
    • 7.5 Others
      • 7.5.1 Global Cancer Monoclonal Antibodies Market by Others, 2024 – 2033 (USD Billion)
  • Chapter 8. Global Cancer Monoclonal Antibodies Market – Distribution Channel Analysis
    • 8.1 Global Cancer Monoclonal Antibodies Market Overview: By Distribution Channel
      • 8.1.1 Global Cancer Monoclonal Antibodies Market Share, By Distribution Channel, 2024 and – 2033
    • 8.2 Hospital Pharmacy
      • 8.2.1 Global Cancer Monoclonal Antibodies Market by Hospital Pharmacy, 2024 – 2033 (USD Billion)
    • 8.3 Online Pharmacy
      • 8.3.1 Global Cancer Monoclonal Antibodies Market by Online Pharmacy, 2024 – 2033 (USD Billion)
    • 8.4 Retail Pharmacy
      • 8.4.1 Global Cancer Monoclonal Antibodies Market by Retail Pharmacy, 2024 – 2033 (USD Billion)
  • Chapter 9. Cancer Monoclonal Antibodies Market – Regional Analysis
    • 9.1 Global Cancer Monoclonal Antibodies Market Regional Overview
    • 9.2 Global Cancer Monoclonal Antibodies Market Share, by Region, 2024 & – 2033 (USD Billion)
    • 9.3. North America
      • 9.3.1 North America Cancer Monoclonal Antibodies Market, 2024 – 2033 (USD Billion)
        • 9.3.1.1 North America Cancer Monoclonal Antibodies Market, by Country, 2024 – 2033 (USD Billion)
    • 9.4 North America Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033
      • 9.4.1 North America Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 9.5 North America Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033
      • 9.5.1 North America Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033 (USD Billion)
    • 9.6 North America Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033
      • 9.6.1 North America Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033 (USD Billion)
    • 9.7 North America Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033
      • 9.7.1 North America Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 9.8. Europe
      • 9.8.1 Europe Cancer Monoclonal Antibodies Market, 2024 – 2033 (USD Billion)
        • 9.8.1.1 Europe Cancer Monoclonal Antibodies Market, by Country, 2024 – 2033 (USD Billion)
    • 9.9 Europe Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033
      • 9.9.1 Europe Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 9.10 Europe Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033
      • 9.10.1 Europe Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033 (USD Billion)
    • 9.11 Europe Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033
      • 9.11.1 Europe Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033 (USD Billion)
    • 9.12 Europe Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033
      • 9.12.1 Europe Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 9.13. Asia Pacific
      • 9.13.1 Asia Pacific Cancer Monoclonal Antibodies Market, 2024 – 2033 (USD Billion)
        • 9.13.1.1 Asia Pacific Cancer Monoclonal Antibodies Market, by Country, 2024 – 2033 (USD Billion)
    • 9.14 Asia Pacific Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033
      • 9.14.1 Asia Pacific Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 9.15 Asia Pacific Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033
      • 9.15.1 Asia Pacific Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033 (USD Billion)
    • 9.16 Asia Pacific Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033
      • 9.16.1 Asia Pacific Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033 (USD Billion)
    • 9.17 Asia Pacific Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033
      • 9.17.1 Asia Pacific Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 9.18. Latin America
      • 9.18.1 Latin America Cancer Monoclonal Antibodies Market, 2024 – 2033 (USD Billion)
        • 9.18.1.1 Latin America Cancer Monoclonal Antibodies Market, by Country, 2024 – 2033 (USD Billion)
    • 9.19 Latin America Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033
      • 9.19.1 Latin America Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 9.20 Latin America Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033
      • 9.20.1 Latin America Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033 (USD Billion)
    • 9.21 Latin America Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033
      • 9.21.1 Latin America Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033 (USD Billion)
    • 9.22 Latin America Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033
      • 9.22.1 Latin America Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033 (USD Billion)
    • 9.23. The Middle-East and Africa
      • 9.23.1 The Middle-East and Africa Cancer Monoclonal Antibodies Market, 2024 – 2033 (USD Billion)
        • 9.23.1.1 The Middle-East and Africa Cancer Monoclonal Antibodies Market, by Country, 2024 – 2033 (USD Billion)
    • 9.24 The Middle-East and Africa Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033
      • 9.24.1 The Middle-East and Africa Cancer Monoclonal Antibodies Market, by Route of Administration, 2024 – 2033 (USD Billion)
    • 9.25 The Middle-East and Africa Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033
      • 9.25.1 The Middle-East and Africa Cancer Monoclonal Antibodies Market, by Application, 2024 – 2033 (USD Billion)
    • 9.26 The Middle-East and Africa Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033
      • 9.26.1 The Middle-East and Africa Cancer Monoclonal Antibodies Market, by End-Users, 2024 – 2033 (USD Billion)
    • 9.27 The Middle-East and Africa Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033
      • 9.27.1 The Middle-East and Africa Cancer Monoclonal Antibodies Market, by Distribution Channel, 2024 – 2033 (USD Billion)
  • Chapter 10. Company Profiles
    • 10.1 Amgen Inc.
      • 10.1.1 Overview
      • 10.1.2 Financials
      • 10.1.3 Product Portfolio
      • 10.1.4 Business Strategy
      • 10.1.5 Recent Developments
    • 10.2 AstraZeneca plc
      • 10.2.1 Overview
      • 10.2.2 Financials
      • 10.2.3 Product Portfolio
      • 10.2.4 Business Strategy
      • 10.2.5 Recent Developments
    • 10.3 Eli Lilly and Company
      • 10.3.1 Overview
      • 10.3.2 Financials
      • 10.3.3 Product Portfolio
      • 10.3.4 Business Strategy
      • 10.3.5 Recent Developments
    • 10.4 AbbVie Inc.
      • 10.4.1 Overview
      • 10.4.2 Financials
      • 10.4.3 Product Portfolio
      • 10.4.4 Business Strategy
      • 10.4.5 Recent Developments
    • 10.5 Genentech Inc. (a subsidiary of Roche)
      • 10.5.1 Overview
      • 10.5.2 Financials
      • 10.5.3 Product Portfolio
      • 10.5.4 Business Strategy
      • 10.5.5 Recent Developments
    • 10.6 Biogen Inc.
      • 10.6.1 Overview
      • 10.6.2 Financials
      • 10.6.3 Product Portfolio
      • 10.6.4 Business Strategy
      • 10.6.5 Recent Developments
    • 10.7 Pfizer Inc.
      • 10.7.1 Overview
      • 10.7.2 Financials
      • 10.7.3 Product Portfolio
      • 10.7.4 Business Strategy
      • 10.7.5 Recent Developments
    • 10.8 Sanofi S.A.
      • 10.8.1 Overview
      • 10.8.2 Financials
      • 10.8.3 Product Portfolio
      • 10.8.4 Business Strategy
      • 10.8.5 Recent Developments
    • 10.9 Seattle Genetics Inc.
      • 10.9.1 Overview
      • 10.9.2 Financials
      • 10.9.3 Product Portfolio
      • 10.9.4 Business Strategy
      • 10.9.5 Recent Developments
    • 10.10 Takeda Pharmaceutical Company Limited
      • 10.10.1 Overview
      • 10.10.2 Financials
      • 10.10.3 Product Portfolio
      • 10.10.4 Business Strategy
      • 10.10.5 Recent Developments
    • 10.11 F. Hoffmann-La Roche Ltd.
      • 10.11.1 Overview
      • 10.11.2 Financials
      • 10.11.3 Product Portfolio
      • 10.11.4 Business Strategy
      • 10.11.5 Recent Developments
    • 10.12 Merck & Co. Inc.
      • 10.12.1 Overview
      • 10.12.2 Financials
      • 10.12.3 Product Portfolio
      • 10.12.4 Business Strategy
      • 10.12.5 Recent Developments
    • 10.13 Bristol Myers Squibb Company
      • 10.13.1 Overview
      • 10.13.2 Financials
      • 10.13.3 Product Portfolio
      • 10.13.4 Business Strategy
      • 10.13.5 Recent Developments
    • 10.14 Johnson & Johnson
      • 10.14.1 Overview
      • 10.14.2 Financials
      • 10.14.3 Product Portfolio
      • 10.14.4 Business Strategy
      • 10.14.5 Recent Developments
    • 10.15 Novartis International AG
      • 10.15.1 Overview
      • 10.15.2 Financials
      • 10.15.3 Product Portfolio
      • 10.15.4 Business Strategy
      • 10.15.5 Recent Developments
    • 10.16 Others.
      • 10.16.1 Overview
      • 10.16.2 Financials
      • 10.16.3 Product Portfolio
      • 10.16.4 Business Strategy
      • 10.16.5 Recent Developments
List Of Figures

Figures No 1 to 35

List Of Tables

Tables No 1 to 102

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2032

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2032
  • Market revenue estimates and forecasts up to 2032, by technology
  • Market revenue estimates and forecasts up to 2032, by application
  • Market revenue estimates and forecasts up to 2032, by type
  • Market revenue estimates and forecasts up to 2032, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Amgen Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • AbbVie Inc.
  • Genentech Inc. (a subsidiary of Roche)
  • Biogen Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Seattle Genetics Inc.
  • Takeda Pharmaceutical Company Limited
  • Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Bristol Myers Squibb Company
  • Johnson & Johnson
  • Novartis International AG
  • Others

FAQs

The key factors driving the Market are Increasing Cancer Incidence, Advancements in Biotechnology, Emphasis on Personalized Medicine, R&D Investments, Diagnostic Expansion And Global Market Expansion.

The “Non-Hodgkin Lymphoma” had the largest share in the global market for Cancer Monoclonal Antibodies.

The “Intravenous (IV)” category dominated the market in 2023.

The key players in the market are Amgen Inc., AstraZeneca plc, Eli Lilly and Company, AbbVie Inc., Genentech Inc. (a subsidiary of Roche), Biogen Inc., Pfizer Inc., Sanofi S.A., Seattle Genetics Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Novartis International AG, Others.

“Europe” had the largest share in the Cancer Monoclonal Antibodies Market.

The global market is projected to grow at a CAGR of 8.2% during the forecast period, 2024-2033.

The Cancer Monoclonal Antibodies Market size was valued at USD 113.8 Billion in 2024.

PURCHASE OPTIONS

$

3990


$

4990


$

5990


$

2290


$

2290

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • Report in your Language.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Report in your Language.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • In-Depth Company Profiles.
  • SWOT Analysis.
  • Identify your Competitors.
  • Recent Development Analysis.
  • Competitor Pricing Strategies.
  • Competitor Marketing Strategies.
  • Competitor Positioning and Messaging.
  • Competitor Product’s Strengths.
  • Free 20% or 10 Hours of Customisation.
  • 15% Discount on your Next Purchase.
  • Upgradable to other licenses.
  • PDF Format.
  • Permission to Print the Report.

Want to customize this report?
100% FREE CUSTOMIZATION!